<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36596904</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-0100</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Endocrine</Title><ISOAbbreviation>Endocrine</ISOAbbreviation></Journal><ArticleTitle>A prospective follow-up on thyroid function, thyroid autoimmunity and long COVID among 250 COVID-19 survivors.</ArticleTitle><Pagination><StartPage>380</StartPage><EndPage>391</EndPage><MedlinePgn>380-391</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12020-022-03281-8</ELocationID><Abstract><AbstractText Label="PURPOSE">We evaluated the evolution of thyroid function and autoimmunity among COVID-19 survivors over 6 months in relation to interferon beta-1b treatment and long COVID.</AbstractText><AbstractText Label="METHODS">We included COVID-19 survivors managed in a major COVID-19 centre between July 2020 and May 2021 who were reassessed three and/or six months after acute COVID-19. Thyroid function tests (TFTs) and anti-thyroid antibody titres were measured at acute COVID-19, 3-month and 6-month.</AbstractText><AbstractText Label="RESULTS">250 COVID-19 survivors were included (mean age 52.7 years, 50.4% men). Persistent thyroid function abnormalities were more likely in those with abnormal TFTs in acute COVID-19 (P&#x2009;&lt;&#x2009;0.001). Among 51 patients with abnormal TFTs in acute COVID-19, 82.4% resolved upon follow-up. Of 199 patients with normal TFTs in acute COVID-19, only 4.5% had incident abnormal TFTs, more likely in interferon-treated patients (P&#x2009;=&#x2009;0.044) and none clinically overt. Among 129 patients with complete 6-month follow-up for anti-thyroid antibody titres, there was no significant change overall, except for modest increase in anti-thyroid antibody titres among the 84 interferon-treated patients (P&#x2009;&lt;&#x2009;0.05 at both 3 months and 6 months). Long COVID occurred in 19.5% and 10.4% at 3 and 6 months respectively, where TFTs and anti-thyroid antibody titres were not predictive of its occurrence.</AbstractText><AbstractText Label="CONCLUSION">Over 6 months, most abnormal TFTs in acute COVID-19 resolved, with no significant incident thyroid dysfunction. SARS-CoV-2 infection did not lead to change in thyroid autoimmunity, while interferon treatment was associated with modest increase in anti-thyroid antibody titres. Thyroid function and anti-thyroid antibodies did not play a significant role in long COVID.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>David Tak Wai</ForeName><Initials>DTW</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsoi</LastName><ForeName>Kimberly Hang</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chi Ho</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Chloe Yu Yan</ForeName><Initials>CYY</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fong</LastName><ForeName>Carol Ho Yi</ForeName><Initials>CHY</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Alan Chun Hong</ForeName><Initials>ACH</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tam</LastName><ForeName>Anthony Raymond</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Polly</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Tip Yin</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Chun Yiu</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Division of Chemical Pathology, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Ching Wan</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>To</LastName><ForeName>Kelvin Kai Wang</ForeName><Initials>KKW</Initials><AffiliationInfo><Affiliation>Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Wing Sun</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>Yu Cho</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Ivan Fan Ngai</ForeName><Initials>IFN</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Kathryn Choon Beng</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Karen Siu Ling</ForeName><Initials>KSL</Initials><Identifier Source="ORCID">0000-0001-5757-541X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. ksllam@hku.hk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Endocrine</MedlineTA><NlmUniqueID>9434444</NlmUniqueID><ISSNLinking>1355-008X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="Y">Thyroid Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">interferons</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">thyroid function tests</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>3</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36596904</ArticleId><ArticleId IdType="pmc">PMC9810240</ArticleId><ArticleId IdType="doi">10.1007/s12020-022-03281-8</ArticleId><ArticleId IdType="pii">10.1007/s12020-022-03281-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the Endocrine System: A Mini-review. Endocrinology. 2022;163:bqab203. doi: 10.1210/endocr/bqab203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endocr/bqab203</ArticleId><ArticleId IdType="pmc">PMC8500009</ArticleId><ArticleId IdType="pubmed">34543404</ArticleId></ArticleIdList></Reference><Reference><Citation>Poma AM, Basolo A, Bonuccelli D, et al. Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19. Thyroid. 2021;31:1766&#x2013;1775. doi: 10.1089/thy.2021.0345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2021.0345</ArticleId><ArticleId IdType="pubmed">34541878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotondi M, Coperchini F, Ricci G, et al. Detection of SARS-COV-2 receptor ACE-2 mRNA in thyroid cells: a clue for COVID-19-related subacute thyroiditis. J. Endocrinol. Invest. 2021;44:1085&#x2013;1090. doi: 10.1007/s40618-020-01436-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01436-w</ArticleId><ArticleId IdType="pmc">PMC7538193</ArticleId><ArticleId IdType="pubmed">33025553</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini F, Ricci G, Croce L, et al. Modulation of ACE-2 mRNA by inflammatory cytokines in human thyroid cells: a pilot study. Endocrine. 2021;74:638&#x2013;645. doi: 10.1007/s12020-021-02807-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02807-w</ArticleId><ArticleId IdType="pmc">PMC8256224</ArticleId><ArticleId IdType="pubmed">34224085</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SA, Phylactou M, Patel B, et al. Normal Adrenal and Thyroid Function in Patients Who Survive COVID-19 Infection. J. Clin. Endocrinol. Metab. 2021;106:2208&#x2013;2220. doi: 10.1210/clinem/dgab349.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab349</ArticleId><ArticleId IdType="pmc">PMC8194556</ArticleId><ArticleId IdType="pubmed">34008009</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal A, Gupta Y, Kalaivani M, Tandon N. Mild and asymptomatic SARS-CoV-2 infection is not associated with progression of thyroid dysfunction or thyroid autoimmunity. Clin. Endocrinol. (Oxf.) 2022;5:7&#x2013;9. doi: 10.1111/cen.14731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.14731</ArticleId><ArticleId IdType="pmc">PMC9111349</ArticleId><ArticleId IdType="pubmed">35384011</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, et al. A guide to immunotherapy for COVID-19. Nat. Med. 2022;28:39&#x2013;50. doi: 10.1038/s41591-021-01643-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01643-9</ArticleId><ArticleId IdType="pubmed">35064248</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo BT, Marik P, Kory P, et al. The time to offer treatments for COVID-19. Expert Opin. Investig. Drugs. 2021;30:505&#x2013;518. doi: 10.1080/13543784.2021.1901883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2021.1901883</ArticleId><ArticleId IdType="pmc">PMC8074648</ArticleId><ArticleId IdType="pubmed">33721548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DTW, Hung IFN, Lee CH, et al. The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors. Front Endocrinol. (Lausanne) 2021;12:746602. doi: 10.3389/fendo.2021.746602.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.746602</ArticleId><ArticleId IdType="pmc">PMC8515032</ArticleId><ArticleId IdType="pubmed">34659128</ArticleId></ArticleIdList></Reference><Reference><Citation>Siriwardhane T, Krishna K, Ranganathan V, et al. Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease. Autoimmune Dis. 2019;2019:1684074. doi: 10.1155/2019/1684074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1684074</ArticleId><ArticleId IdType="pmc">PMC6699358</ArticleId><ArticleId IdType="pubmed">31467701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>H.M. Rando, T.D. Bennett, J.B. Byrd, et al. (2021) Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv. 10.1101/2021.03.20.21253896</Citation></Reference><Reference><Citation>Murray T. Unpacking &#x201c;long COVID.&#x201d;. CMAJ. 2021;193:E318&#x2013;E319. doi: 10.1503/cmaj.1095923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.1095923</ArticleId><ArticleId IdType="pmc">PMC8034303</ArticleId><ArticleId IdType="pubmed">33649174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DTW, Lee CH, Chow WS, et al. Thyroid Dysfunction in Relation to Immune Profile, Disease Status and Outcome in 191 Patients with COVID-19. J. Clin. Endocrinol. Metab. 2020;106:e926&#x2013;e935. doi: 10.1210/clinem/dgaa813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa813</ArticleId><ArticleId IdType="pmc">PMC7665541</ArticleId><ArticleId IdType="pubmed">33141191</ArticleId></ArticleIdList></Reference><Reference><Citation>I.F.N. Hung, K.C. Lung, E.Y.K. Tso et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet (Lond., Engl.) 395, 1695&#x2013;1704 (2020). 10.1016/S0140-6736(20)31042-4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211500</ArticleId><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Online appointments for Universal Community Testing Programme to begin tomorrow. https://www.info.gov.hk/gia/general/202008/28/P2020082800837.htm. Accessed 3 Mar 2021</Citation></Reference><Reference><Citation>Lui DTW, Lee CH, Chow WS, et al. Long COVID in Patients with Mild to Moderate Disease: Do Thyroid Function and Autoimmunity Play a Role. Endocr. Pr. 2021;27:894&#x2013;902. doi: 10.1016/j.eprac.2021.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eprac.2021.06.016</ArticleId><ArticleId IdType="pmc">PMC8257401</ArticleId><ArticleId IdType="pubmed">34237471</ArticleId></ArticleIdList></Reference><Reference><Citation>W.M. Chan, J.D. Ip, A.W.H. Chu et al. Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole-genome sequencing. J. Med Virol. 92, 2725&#x2013;2734 (2020). 10.1002/jmv.26140</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300711</ArticleId><ArticleId IdType="pubmed">32501535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui D.T.W., Lee C.H., Chow W.S., et al. (2021) Role of non-thyroidal illness syndrome in predicting adverse outcomes in COVID-19 patients predominantly of mild-to-moderate severity. Clin Endocrinol (Oxf). 10.1111/cen.14476</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8250365</ArticleId><ArticleId IdType="pubmed">33813743</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Yan L, Wang N, et al. Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients. Clin. Infect. Dis. 2020;71:793&#x2013;798. doi: 10.1093/cid/ciaa345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa345</ArticleId><ArticleId IdType="pmc">PMC7184442</ArticleId><ArticleId IdType="pubmed">32221523</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle Threshold Value. Clin. Infect. Dis. 2020;71(16):2252&#x2013;2254. doi: 10.1093/cid/ciaa619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa619</ArticleId><ArticleId IdType="pmc">PMC7314112</ArticleId><ArticleId IdType="pubmed">32435816</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition). http://kjfy.meetingchina.org/msite/news/show/cn/3337.html. Accessed 23 Aug 2020</Citation></Reference><Reference><Citation>Yuan S, Yin X, Meng X, et al. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Nature. 2021;593:418&#x2013;423. doi: 10.1038/s41586-021-03431-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03431-4</ArticleId><ArticleId IdType="pubmed">33727703</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung IFN. Treatment of coronavirus disease 2019. Curr. Opin. HIV AIDS. 2020;15:336&#x2013;340. doi: 10.1097/COH.0000000000000652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000652</ArticleId><ArticleId IdType="pubmed">33002954</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisan Dabija R, Antohe I, Trofor A, Antoniu SA. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice. Expert Rev. Anti Infect. Ther. 2021;19:1553&#x2013;1562. doi: 10.1080/14787210.2021.1933437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1933437</ArticleId><ArticleId IdType="pmc">PMC8171006</ArticleId><ArticleId IdType="pubmed">34015985</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcellona D, Fanni D, Gerosa C, et al. Heparins and 2019-nCoV infection: a narrative review. Eur. Rev. Med Pharm. Sci. 2021;25:3594&#x2013;3606. doi: 10.26355/eurrev_202105_25842.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202105_25842</ArticleId><ArticleId IdType="pubmed">34002834</ArticleId></ArticleIdList></Reference><Reference><Citation>Amenta EM, Spallone A, Rodriguez-Barradas MC, et al. Postacute covid-19: An overview and approach to classification. Open Forum Infect. Dis. 2020;7:ofaa509. doi: 10.1093/ofid/ofaa509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa509</ArticleId><ArticleId IdType="pmc">PMC7665635</ArticleId><ArticleId IdType="pubmed">33403218</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur. Thyroid J. 2013;2:215&#x2013;228. doi: 10.1159/000356507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000356507</ArticleId><ArticleId IdType="pmc">PMC3923601</ArticleId><ArticleId IdType="pubmed">24783053</ArticleId></ArticleIdList></Reference><Reference><Citation>Monzani F, Caraccio N, Casolaro A, et al. Long-term interferon &#x3b2;-1b therapy for MS: Is routine thyroid assessment always useful? Neurology. 2000;55:549&#x2013;552. doi: 10.1212/WNL.55.4.549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.55.4.549</ArticleId><ArticleId IdType="pubmed">10953190</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisullo G, Calabrese M, Tortorella C, et al. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: An Italian multicenter study. Mult. Scler. J. 2014;20:1265&#x2013;1268. doi: 10.1177/1352458514521311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458514521311</ArticleId><ArticleId IdType="pubmed">24515732</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo B, Tan T, Clarke SA, et al. Thyroid Function Before, During, and After COVID-19. J. Clin. Endocrinol. Metab. 2021;106:e803&#x2013;e811. doi: 10.1210/clinem/dgaa830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa830</ArticleId><ArticleId IdType="pmc">PMC7823247</ArticleId><ArticleId IdType="pubmed">33180932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasagi K, Takahashi N, Inoue G, et al. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. Thyroid. 2009;19:937&#x2013;944. doi: 10.1089/thy.2009.0205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2009.0205</ArticleId><ArticleId IdType="pubmed">19678737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzocaro A, Colombo P, Vena W, et al. Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study. Endocrine. 2021;73:255&#x2013;260. doi: 10.1007/s12020-021-02758-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-021-02758-2</ArticleId><ArticleId IdType="pmc">PMC8161706</ArticleId><ArticleId IdType="pubmed">34047879</ArticleId></ArticleIdList></Reference><Reference><Citation>A.R. Tam, R.R. Zhang, K.C. Lung, et al. (2022) Early treatment of high-risk hospitalized COVID-19 patients with a combination of interferon beta-1b and remdesivir: a phase 2 open-label randomized controlled trial. Clin Infect Dis. 10.1093/cid/ciac523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278225</ArticleId><ArticleId IdType="pubmed">35762834</ArticleId></ArticleIdList></Reference><Reference><Citation>Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir. Med. 2021;9:498&#x2013;510. doi: 10.1016/S2213-2600(20)30566-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30566-X</ArticleId><ArticleId IdType="pmc">PMC7906707</ArticleId><ArticleId IdType="pubmed">33556319</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2021;9:196&#x2013;206. doi: 10.1016/S2213-2600(20)30511-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30511-7</ArticleId><ArticleId IdType="pmc">PMC7836724</ArticleId><ArticleId IdType="pubmed">33189161</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Peto R, Henao-Restrepo A-M, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N. Engl. J. Med. 2021;384:497&#x2013;511. doi: 10.1056/NEJMoa2023184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023184</ArticleId><ArticleId IdType="pmc">PMC7727327</ArticleId><ArticleId IdType="pubmed">33264556</ArticleId></ArticleIdList></Reference><Reference><Citation>Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-&#x3b2; 1a or 1b therapy: Predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab. 2005;90:4133&#x2013;4137. doi: 10.1210/jc.2004-2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2004-2326</ArticleId><ArticleId IdType="pubmed">15811929</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R, Joshi A, Bhadada SK, et al. Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence. Endocr. Pr. 2022;28:425&#x2013;432. doi: 10.1016/j.eprac.2022.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eprac.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC8832848</ArticleId><ArticleId IdType="pubmed">35158058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DTW, Lee CH, Cheung CYY, et al. Effect of COVID-19 Vaccines on Thyroid Function and Autoimmunity and Effect of Thyroid Autoimmunity on Antibody Response. J. Clin. Endocrinol. Metab. 2022;107:e3781&#x2013;e3789. doi: 10.1210/clinem/dgac355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgac355</ArticleId><ArticleId IdType="pmc">PMC9214146</ArticleId><ArticleId IdType="pubmed">35679093</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Lui DTW, Xiong X, et al. Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients. BMC Med. 2022;20:339. doi: 10.1186/s12916-022-02548-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02548-1</ArticleId><ArticleId IdType="pmc">PMC9560718</ArticleId><ArticleId IdType="pubmed">36229814</ArticleId></ArticleIdList></Reference><Reference><Citation>Thvilum M, Brandt F, Brix TH, Heged&#xfc;s L. Month of birth is associated with the subsequent diagnosis of autoimmune hypothyroidism. A nationwide Danish register-based study. Clin. Endocrinol. (Oxf.) 2017;87(6):832&#x2013;837. doi: 10.1111/cen.13425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen.13425</ArticleId><ArticleId IdType="pubmed">28727153</ArticleId></ArticleIdList></Reference><Reference><Citation>De Grande LA, Goossens K, Van Uytfanghe K, et al. Using &#x201c;big data&#x201d; to describe the effect of seasonal variation in thyroid-stimulating hormone. Clin. Chem. Lab Med. 2017;55:e34&#x2013;&#x2013;e36. doi: 10.1515/cclm-2016-0500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2016-0500</ArticleId><ArticleId IdType="pubmed">27447241</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>